Login to Your Account



Clinic Roundup


Friday, October 7, 2011
Peregrine Pharmaceuticals Inc., of Tustin, Calif., said it completed enrollment and randomization of 121 patients in a Phase II trial of bavituximab in combination with docetaxel in previously treated, locally advanced or metastatic non-small-cell lung cancer (NSCLC).

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription